autophagy-enhancing drug promotes degradation mutant alpha antitrypsin z reduces hepatic fibrosis 
classical form alpha-antitrypsin deficiency point mutation alters folding liver-derived secretory glycoprotein renders aggregation-prone addition decreased serum concentrations disorder characterized accumulation mutant alpha-antitrypsin z atz variant inside cells causing hepatic fibrosis and/or carcinogenesis gain-of-toxic function mechanism proteasomal autophagic pathways known mediate degradation atz show autophagy-enhancing drug carbamazepine cbz decreased hepatic load atz hepatic fibrosis mouse model deficiency-associated liver disease results provide basis testing cbz extensive clinical safety profile patients deficiency also provide proof principle therapeutic use autophagy enhancers 
